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TARGETS, INTERVENTIONS AND COST-EFFECTIVENESS
CHAPTER 9
EFFECTS OF TARGETING DISEASE AND 
MEDICATION MANAGEMENT 
INTERVENTIONS TOWARDS PATIENTS 
WITH COPD
Van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ.




ENHANCING ADHERENCE IN PATIENTS WITH COPD
ABSTRACT
Aims
Suboptimal adherence in Chronic Obstructive Pulmonary Disease (COPD) patients is associated 
with decreased clinical and economic outcomes. Intervention programs, targeted at patients 
with suboptimal adherence and symptoms, offer opportunities for cost-effective COPD care. 
We aimed to assess the effects of the targeted COPD-intervention program Medication Moni-
toring and Optimization (MeMO).
Methods
Twenty settings participated in this 1-year real-world study with a pre-test/post-test design. 
Patients with a physician-confirmed COPD diagnosis, oral corticosteroid use,  suboptimal ad-
herence and Clinical COPD Questionnaire (CCQ)-score ≥1 were selected by community phar-
macists. Pharmacy interventions included inhalation-instruction, medication information and 
motivational interviewing regarding adherence and smoking cessation. Proposals for dose-, 
medication- and/or inhaler change and physical activity- or diet recommendations were dis-
cussed with the general practitioner (GP), physiotherapist or dietician. Primary endpoint was 
the change in CCQ-score. Secondary outcomes were adherence, exacerbations, healthcare uti-
lization, quality of life (EQ-5D), dyspnea by modified Medical Research Council (mMRC) and 
cost-effectiveness.
Results
Interventions were performed in 88 patients (mean age: 69; 52% male; mean CCQ: 2.10). 
Most performed interventions were inhalation-instruction (89%), medication education (98%) 
and adherence counseling (58%). Respectively 9%, 45% and 16% were referred to GP, phys-
iotherapist or dietician. After 1 year, mean CCQ-decrement was 0.12 and 38% had a clinical 
relevant improvement. There was a significant decrease (-0.82) in exacerbations. Adherence, 
mMRC and EQ-5D did not change. Medication costs were €26 higher, intervention costs €33, 
but total healthcare costs were €333 lower. The small sample size and lack of control group 
were the main limitations.
Conclusion
By specifically targeting COPD patients with potential gain for improvement, the MeMO-COPD 
program seems an efficient and cost-saving method to improve patients’ health outcomes.
181
9
TARGETS, INTERVENTIONS AND COST-EFFECTIVENESS
INTRODUCTION
Disease and medication management programs for patients with Chronic Obstructive Pulmo-
nary Disease (COPD) have shown promising, but also contradictive results. 1-4 A major factor 
predicting a positive result may be related to the population included in the considered study. 
5 The RECODE-study (N=1,086) assessed an integrated disease management program and 
showed no effects. According to the authors, one of the reasons for this limited effect was re-
lated to the lack of selection of patients that might have the largest benefits. 3 
A COPD subpopulation that offers large potential room for improvement is the group of 
non-adherent patients. Non-adherence to inhaled medication in COPD patients is an increas-
ingly recognised healthcare issue that is not only associated with diminished health effects, 
but also with higher total treatment costs. 6, 7 Optimal adherence encompasses continuous 
use (persistence) as well as use in accordance with the instructions of the prescriber. The latter 
means patients should follow to the advised dosing regimen, while performing their inhalation 
technique as instructed. 8 
So far, interventions to improve adherence in patients with COPD have shown some promising 
effects regarding adherence, exacerbations and costs. 9, 10 However, long-term evidence and 
effects on quality of life are less clear. Furthermore, the key aspects that contribute to the (cost) 
effectiveness of disease management and adherence enhancing interventions still need to be 
uncovered. 11, 12 
In other chronic disease areas, targeted disease management programs like Medication Mon-
itoring and Optimization (MeMO) have shown their value regarding adherence, cost-effec-
tiveness and patient satisfaction. 13-16 Recently, the MeMO-COPD program was launched in 
several Dutch community pharmacies that were embedded in local primary care settings. These 
integrated community care settings, with strong collaborations between general practitioners 
(GPs), pharmacists, primary care nurses and physiotherapists offer possibilities for effective, 
continuous, multidisciplinary care for COPD patients. 17 In the MeMO program, community 
pharmacists play an integral role in the proactive detection and optimization of suboptimal 
pharmacotherapy in patients with COPD. Due to the possession of longitudinal data on phar-
macy dispenses, combined with physician confirmed diagnoses and Clinical COPD Question-
naire (CCQ)-scores, the MeMO program could specifically and efficiently target those COPD 
patients with suboptimal adherence as well as symptoms and risk for exacerbations. Conse-
quently, not all patients are intervened, like in ‘one-size-fits-all’ intervention programs, but only 
those that may have the greatest potential benefits. Therefore, this strategy is expected to have 
a favourable impact on the programs’ effectiveness and cost-effectiveness.
The aim of this study was to assess the effectiveness and cost-effectiveness of the targeted 
MeMO intervention program in terms of different health outcomes.
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METHODS
Study design
This was a pragmatic study with a pre-test/post-test design. Patients were recruited from com-
munity pharmacies spread out over The Netherlands, between October 2013 and February 
2014. All pharmacies were part of the Connecting Care collaborative (www.connecting-care.
nl). These are pharmacies with well-established collaborations with their local primary care team 
including GPs, physiotherapists and primary care nurses. The follow-up period was 1 year. Eth-
ical approval was granted by the Zorggroep Noorderbreedte (RTPO 813a).
Participation and local primary care team involvement
At start, all 22 Connecting Care pharmacies, including both rural and urban pharmacies, agreed 
to participate in the study. Of the 22 pharmacies that initially agreed to participate, two phar-
macies dropped out shortly after the educational session. One pharmacy had to leave the study 
due to time constraints and the other pharmacy had to stop the study because of interference 
with another primary care COPD study in which many of their patients already participated in.
The pharmacist(s) that functioned as project leads for each pharmacy received training about 
COPD pharmacotherapy optimization (with special attention on the handling of non-adherence 
management), COPD guidelines, referral criteria, as well as instructions on the study protocol 
and the technical procedure on how to extract their patients’ data from the pharmacy infor-
mation system. Pharmacists received written material to educate their pharmacy colleagues not 
attending the educational session and to support their interventions and were free to involve 
other members of their local primary care team.
Patient selection and inclusion process: targeting the intervention
Patients were pre-selected according to the algorithm presented in figure 1. Pharmacists were 
instructed to select patients with a physician-confirmed COPD diagnosis and the use of mini-
mal one short course of oral corticosteroids with or without antibiotics (indicating a likelihood 
of exacerbations) in the previous year, as well as suboptimal adherence to inhaled respiratory 
maintenance medication. Suboptimal adherence was defined as the discontinuation of a respi-
ratory maintenance drug or continuous use with less than 80% of the prescribed doses taken 
(underuse) or more than 120% of the doses taken (overuse), as calculated by the proportion 
of days covered (PDC). The PDC over the last year was obtained by dividing the total number 
of days with medication available, when used as prescribed, by 365 days. The use of oral cor-
ticosteroids was more important than the adherence criterion as dispense adherence may not 
guarantee actual (correct) intake. Patients were invited for an intake and completed the CCQ 
in the pharmacy. Only patients with a total CCQ-score or a CCQ-subscore ≥ 1 were invited to 
participate in the MeMO-program. The pharmacist discussed the inclusion with the GP in order 
to reassure eligibility and to minimize the possibility that patients would be included in other 
COPD studies. All patients signed agreement before participating in the study. 
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Figure 1: Targeted interventions to optimize COPD therapy: selecting patients with largest potential for improvement
Interventions
The MeMO-COPD intervention program involved a patient counseling session, followed by 
a second consultation at three months and active monitoring for suboptimal adherence at six 
and nine months. Interventions that could be performed during the initial session included (re-
inforcement of) inhalation instructions, provision of additional information on the medication 
used (e.g. mechanism of action, side-effects), counseling on several aspects of adherence (e.g. 
beliefs and expectations, reminders, highlighting importance of continuous use in accordance 
with prescription)  tailored to the type of non-adherence and smoking cessation and recom-
mendations regarding self-management. In some cases (change of dose regimen, change of 
type of inhaler or change of medication), the GP was contacted by the pharmacist or patients 
were immediately referred to the GP. Pharmacists were recommended to always advise physical 
activity, with or without recommendation to contact the physiotherapist. In case of low (<21) or 
high (>30) body mass index (BMI), they were recommended to refer to a dietician.
In specific cases (e.g. after a recommendation for dose or inhaler change), a follow-up inter-
vention was undertaken as a supplement to the first intervention. These interventions included, 
after evaluation of patients’ medication profiles, a second patient counseling session or consul-
tation with the GP. The monitoring  at six and nine months was performed using the pharmacy 
dispense information system. Only when deemed relevant by the pharmacist (e.g. in case of 
increased use of short-acting bronchodilators), an active intervention was performed at these 
time points. At one year, an evaluation was performed. All interventions, along with the time 
investment per intervention, were logged by the participating pharmacists.
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Outcome measures
The primary study effectiveness endpoint was the mean change in CCQ-score, between base-
line and one year after intervention. Secondary outcomes included medication adherence, ex-
acerbations, healthcare utilization, general quality of life, dyspnea and cost-effectiveness, as 
specified in the following sections.
CCQ
The mean change in CCQ-score was the primary study endpoint. The CCQ is a 10-item vali-
dated instrument for measuring COPD specific quality of life.18 The CCQ ranges from 0 (good 
COPD control) to 6 (no COPD control), provides sub-scores on physical, symptoms and depres-
sion domains and has an established minimal clinically important difference of 0.4. 19 Sub-scores 
as well as the percentage with clinical relevant improvement in CCQ-score were calculated and 
reported.
General quality of life
To measure general quality of life, the EuroQoL 5-Dimensions (EQ-5D) questionnaire was used. 
The five dimensions of the EQ-5D comprise mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. The EQ-5D is a general preference based instrument that enables the 
estimation of utilities, where a utility of 1 represents perfect health and 0 represents a state 
similar to death. The EQ-5D has been validated for use in the Netherlands. 20 
Dyspnea
Dyspnea was measured using the modified Medical Research Council dyspnea score (mMRC). 
The mMRC consists of a 1-item questionnaire asking the extent of dyspnea on a 0 (few dys-
pnea) to 4 (heavy dyspnea) scale. 21
CCQ, EQ-5D and mMRC scores were measured at baseline, after 3 months and after one 
year. Mean CCQ and EQ-5D scores and proportion of patients with mMRC≥2 were compared 
between baseline and three months (short-term effects) and between baseline and one year 
(long-term effects).
Medication adherence
Medication adherence was calculated based on the PDC with COPD maintenance medication 
(long-acting bronchodilators and inhaled corticosteroids) during the year before intervention 
and one year after intervention. To avoid recall bias, medication adherence was directly extract-
ed from the pharmacy dispense system.
Exacerbations
As this study focused on health outcomes and cost-effectiveness, exacerbations were defined 
by healthcare utilization. 22 As such, a community treated exacerbation was defined by the dis-
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pense of a short-course of oral corticosteroids with or without antibiotics (7-14 days). To avoid 
recall bias, these were directly extracted from the pharmacy dispense system over the pre-inter-
vention reference period of 1 year and over the post-intervention period of 1 year. More severe 
exacerbations were patient reported and defined as the number of COPD-related emergency 
department (ED) visits and COPD-related hospitalizations. 
Healthcare utilization and costs
Resource use related to COPD was divided into four categories: (1) intervention costs (2) costs 
of medication, (3) costs of healthcare use and (4) costs due to lost productivity. 
Intervention costs were calculated based on time investment of healthcare providers (obtained 
via self-report) and multiplied by a fixed hourly fee. 10 Healthcare resource use was obtained 
from self-reported questionnaires, in which the patients were retrospectively asked about the 
use of healthcare resources. These included COPD related GP consultations (phone calls or 
visits), specialist visits, visits to the emergency department and hospitalizations. Days of lost 
productivity were also self-reported by the patients (only patients that were not retired). Data 
on the use of medication were extracted from the pharmacy information system as this type of 
resource use is usually prone to recall bias. 23 
The costs of resource use were calculated by multiplying the specific type of resources with their 
unit costs according to Dutch national price lists. 24, 25 
Cost-effectiveness
The cost-effectiveness was calculated with data collected alongside the 1-year time horizon of 
this study. Costs included the sum of all four cost categories as specified above. Effects were 
either expressed as difference in Quality Adjusted Life-Years (QALYs) or CCQ score.
Statistics
Differences in mean outcome values before and after intervention were compared using paired 
samples T-tests. P-values <0.05 were considered statistically significant. For each difference, 
95% confidence intervals (95%CI) were reported. For all statistical analyses, IBM SPSS Statistics 
22 was used.
RESULTS
Participation and local primary care team involvement
In total, 20 different pharmacies were involved in the patient selection process and the perfor-
mance of the interventions and follow-up. Most pharmacies did involve other members of their 
local primary care team, varying from data exchange only to full collaborations and agreements 
on the different tasks to be performed.
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Patient selection process
By using the search algorithm, the 20 pharmacies identified on average 68 patients per pharma-
cy that were dispensed respiratory medication (ATC code R03) and had at least one prescription 
of prednisone or prednisolone (H02AB06, H02AB07) in the previous year. These were about 
19% of the total users of R03 medication. When cross-tabbed with the clinical diagnoses of 
GPs, on average in 25 of the 68 patients (37%), a COPD diagnosis was confirmed. These pa-
tients were assessed for underuse of maintenance medication (LABA, LAMA, ICS) or overuse of 
rescue (SABA, SAMA) or maintenance medication, discussed with the GP and eligible patients 
were invited for an initial assessment (including CCQ). After these additional assessments, on 
average 5 patients per pharmacy (median: 4; interquartile range: 3) were eligible for final inclu-
sion, resulting in a total of 94 patients initiating the study. 6 patients did not complete the study 
due to several reasons (2 moved, 1 died, 1 stopped all medication and 2 were lost to follow-up).
Patient characteristics
88 patients were included in the final study cohort and completed the study. Patients’ charac-
teristics are presented in Table 1. 
Table 1: Patient characteristics (N=88)
Parameter Value
General
Age (mean, SD) 68.8 (7.8)
Male (%) 52.2
BMI (mean, SD) 27.1 (5.1)



















Years since COPD diagnosis (mean, SD) 11.4 (10.1)
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Parameter Value







Spirometric classification (N, %)
I: Mild (FEV1%predicted >80%)
II: Moderate (FEV1%predicted 50-80%)
III: Severe (FEV1%predicted 30-50%)







Exacerbation history in previous year
Community treated exacerbations (mean, SD) 1.84 (1.63)
ED treated exacerbations (mean, SD) 0.24 (0.73)
Hospital treated exacerbations (mean, SD) 0.26 (0.51)
Health status
CCQ score (mean, SD) 2.10 (1.12)











EQ-5D score (mean, SD) 0.74 (0.25)
EQ-5D-VAS (mean, SD) 62.5 (14.9)
Comorbidity (%)






Total number of comorbidities (mean, SD) 1.8 (1.2)
















Total number of respiratory medications (mean, SD) 2.3 (0.99)
Total number of other medication (mean, SD) 4.4 (3.5)
BMI: Body Mass Index; CCQ: Clinical COPD Questionnaire; COPD: Chronic Obstructive Pulmonary Disease; FEV1: 
Forced expiratory volume in 1 second; GP: General Practitioner; ICS: Inhaled corticosteroids; LABA: Long-acting beta 
agonist; LAMA: Long-acting muscarinic antagonist; SABA: Short-acting beta agonist; SAMA: Short-acting muscarinic 
antagonist; SD: Standard deviation
Interventions
Figure 2 provides an overview of all interventions that have been performed in the total pop-
ulation of 88 patients. Most performed interventions in the pharmacy were medication educa-
tion, inhalation instruction and counseling on adherence. Interventions were performed by a 
pharmacist (25%), a pharmaceutical consultant (25%) or a pharmaceutical technician (50%).
Mean initial time investment was 26 minutes (minimum: 3, maximum: 65) per consultation. 
Sometimes a follow-up intervention was needed, which took on average 14 minutes (mini-
mum: 0, maximum: 45). Using a flat hourly fee of €50, the mean intervention costs were €33 
per patient.
Figure 2: Interventions performed
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In table 2, the differences in patient reported health outcomes are shown. Mean CCQ total and 
sub-scores showed improvements 1 year after intervention. However, no statistical significant 
differences were observed except for the CCQ-mental sub-score. In addition, out of the 88 
patients, 53 (60%) improved in total CCQ score and 33 (38%) had a clinical relevant improve-
ment in CCQ score. 17 patients (19%) had a clinical relevant decrease in CCQ score. There 
were no significant differences in EQ-5D and mMRC.
Table 2: Patient reported health outcomes at baseline, 3 months and 1 year.
Outcome Baseline 
(mean)
After 3 months 
(mean)
Difference with baseline 
(95%CI)






























EQ-5D VAS 62.5 NA NA 63.3  0.91 
(-2.07 - 
3.91)




#: Here, not mean, but proportion with mMRC≥2 was used; *significant (p<0.05); CCQ: Clinical COPD Questionnaire; 
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Adherence
Adherence to long-acting bronchodilators was 0.85 before intervention and 0.86 after inter-
vention. Adherence to inhaled corticosteroids was 0.82 before intervention and 0.84 after 
intervention. Differences for both bronchodilators (0.01 [95%CI: -0.04-0.06]) and ICS (0.03 
[95%CI: -0.04-0.10]), were not significant.
Exacerbations
In table 3, the difference in occurrence of exacerbations is shown. All types of exacerbations 
decreased after intervention. The number of total and community treated exacerbations after 1 
year was significantly different compared to baseline.
Table 3: Exacerbations
Exacerbations T=0 T=1 Difference (95%CI)
Community treated exacerbation 1.84 1.25 -0.59 (-0.98 - -0.20)*
ED treated exacerbation 0.24 0.09 -0.15 (-0.32 - 0.02)
Hospital treated exacerbation 0.26 0.18 -0.08 (-0.21 - 0.05)
Total exacerbations 2.34 1.52 -0.82 (-1.28 - -0.36)*
*significant (p<0.05); CI confidence interval; ED: emergency department; T=0: year before  MeMO intervention; T=1; 
year after MeMO  intervention
Healthcare utilization and costs
Table 4 shows the differences in healthcare utilization and costs between baseline and 1 year 
after intervention. After intervention, on average €333 less was spent on healthcare utilizations. 
Intervention and medication costs increased, but costs for other healthcare use decreased (GP 
visits, specialist visits and hospitalizations). Taking into account productivity, cost-savings were 
€268. Note that large confidence intervals applied as only nine patients were still working.
Table 4: Healthcare utilization and costs (€) from a Dutch healthcare payer and societal perspective
Baseline After intervention







N  per patient 
(mean)







varied varied 0 0 varied 33 33 
(30 - 36)*
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Baseline After intervention







N  per patient 
(mean)







1.25 78 98 1.20 78 92 -5 
(-36 - 25)




1.82 493 896 1.13 493 549 -347 
(-841 - 146)












1751 1483 -268 
(-926 - 391)
*significant (p<0.05); CI: Confidence interval; ED: Emergency Department; GP: General practitioner
Cost effectiveness
As both favorable effects and cost-savings were observed, the MeMO-COPD intervention pro-
gram seems to be cost-saving, that is, better health effects at lower costs. 
DISCUSSION
Main findings
Results from this study did not show a significant or clinical relevant increase in total CCQ score 
or generic quality of life. However, 38% of the patients showed a clinical relevant improvement 
in CCQ-score and the total number of exacerbations significantly decreased. Medication costs 
and intervention costs did slightly increase, while other healthcare costs decreased, resulting in 
savings on total healthcare expenses.
Interpretation
In recent years, several previous studies have assessed the effectiveness and cost-effective-
ness of COPD disease management programs performed in Dutch primary care. 1-3 However, 
these interventions were not specifically targeted towards a patient population with potential 
gains. The Dutch study by Kruis et al 3 trained GPs, nurses and physiotherapists and high-
lighted the importance of integrated care. There were no significant effects regarding quality 
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of life, exacerbations or healthcare utilization. The authors suggested that the reason for the 
unfavorable effects were related to the fact that their interventions were targeted at health-
care professionals instead of patients and the little room for improvement in the Dutch patient 
population. Bischoff et al 1 assessed the effects of two types of COPD disease management 
(comprehensive self-management and routine monitoring) versus usual care. This study did 
not specifically target patients with potential gains and did not find any benefits in terms of 
quality of life. Few studies on disease management interventions have been shown to lead to 
an improvement in CCQ-scores, however Chavannes et al 2 reported significant improvements 
in Saint George’s Respiratory Questionnaire (SQRQ) scores after extensive integrated disease 
management. Notably, improvements were greatest in patients with worse disease status, un-
derpinning the value of targeting patients. Furthermore, note that COPD is progressive dis-
ease and no decline in quality of life could therefore be seen as a positive effect. Outside of 
The Netherlands, there have been some COPD intervention studies performed that specifically 
focused on improvement of adherence and/or inhalation technique.  A small Japanese study 
(N=51) by Takemura et al assessed the effects of improving inhalation technique and found, in 
line with our study, significant decreases in exacerbations, however no effect on quality of life. 
26 Khdour et al focused on patient education, medication and breathing techniques in Northern 
Ireland. Also this study showed decreased hospitalizations, but no difference in quality of life 
as measured by total score on the SQRQ. 27 The PHARMACOP-trial was a larger (N=734), Bel-
gium-based study, using motivational interviewing, tailored approaches for different types of 
non-adherence, demo-inhalers and device-unique inhalation technique checklists. The PHAR-
MACOP-strategy was found to both improve adherence, as measured by PDC, and inhalation 
technique and significantly reduced hospital-treated exacerbations. 9 Moreover, even with cost 
of the intervention and higher medication costs, the PHARMACOP-intervention was deemed 
cost-saving because of its reduction in hospitalizations and associated costs. 10 Notably, effects 
on annual hospitalization rates and total costs savings were very similar to our study (decrease 
of 0.07 hospitalizations and cost savings of €227). In addition, a Spanish study showed favour-
able effects of improving adherence in patients with COPD. 28 In our study, no significant overall 
improvement in adherence as measured by PDC was observed, however we noticed (data not 
shown) a minor increase in patients using ICS (69% before versus 72% after intervention) 
and number of non-respiratory medication (4.4 versus 4.6). Of interest, in a subgroup with 
decreased exacerbations (N=55), increase in adherence to ICS was more profound (+/-8%, 
data not shown) than overall increase in ICS adherence (3%). Other explanations for positive 
effects may be related to unobserved changes in inhalation technique, patients’ smoking and 
lifestyle habits or use of other (non-)pharmacological treatments, although those were not 
quantitatively measured. COPD patients typically use multiple medication, therefore it has been 
suggested that improving adherence to one type of medication may impact adherence to other 
medication as well, resulting in larger potential effect sizes of these type of adherence and be-
havior enhancing interventions. 29 Moreover, changing patients’ behavior may lead to an overall 
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‘healthy adherer effect’. Patients are then not only more adherent to their medication, but also 
more aware of the importance of a healthy lifestyle (e.g. smoking cessation, exercise, diets). 30
Strengths & Limitations
This study had several strengths. The real-life setting allowed the study to be performed in a 
group of COPD patients that was representative for primary care treatment, that is, without ex-
cluding patients that are usually excluded in large registration trials (e.g. due to comorbidities). 
As such, the most prevalent (CVD, diabetes, asthma)- and number (1.91) of- comorbidities, 
were in line with a recent observational study, that only included users of COPD maintenance 
medication that assessed the impact of comorbidities (53% had 1 or 2 comorbidities). 31 Only 
a small percentage of patients were lost to follow up. Moreover, due to study visits mostly 
planned during regular primary care contacts, few missing data occurred and this allowed col-
lection of extensive information on patient reported outcomes and healthcare providers’ inter-
ventions. Notably, due to this detailed monitoring of healthcare interventions, this is one of the 
first studies looking further into the success factors of disease management programs in COPD 
that predict favorable effectiveness and cost-effectiveness. Lastly, due to the length of the study 
(1 year), seasonal influence could be minimized.
This study also faced some limitations. Firstly, this study had no control group or randomization; 
rather the patients functioned as their own historical control (pre-post design). For complex 
intervention programs such as these, suitable control patients may be difficult to define. Due 
to the small sample size, as of the limited number of pharmacies that were part of Connecting 
Care, this study was not large enough to observe statistical significant differences on the primary 
endpoint, however several interesting trends were observed, demonstrating the need for larger 
confirmative follow-up studies. Larger studies may also reduce the impact of inter-professional 
differences in implementation and communication skills (including empathy) on final outcomes. 
Regarding the counting of exacerbations, two issues may arise. First, a patient usually has to go 
to the pharmacy to fill his or her prescription each time a new exacerbation occurs. However, it 
may be possible that a patient used leftovers of a previous fill. A second issue is that, contrasting 
to the Dutch GP guidelines, only antibiotics were prescribed and no oral corticosteroids. In both 
cases, this exacerbation was not counted, however this was deemed equally plausible before 
and after intervention. Another limitation, resulting from the pre-post design, was the bias due 
to other interventions that may have been performed. However, we aimed to inform all health-
care providers in the region and results do still well correspond with the study of Tommelein 
et al that used a randomized control design. 9 In addition, several outcome measures (such as 
exacerbations and adherence) were measured objectively, thereby reducing the risk of observer 
and recall-bias. Furthermore, note that this study was performed in a small group of pharma-
cies with high motivation, which may limit generalizability. Lastly, in the current MeMO-COPD 
program, sub-optimal inhalation technique, an important aspect of non-adherence in COPD 
patients, could not be identified on beforehand. However, new technologies, based on acoustic 
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sound algorithms to identify sub-optimal inhalation technique, are promising and can assist in 
optimizing the targeting process.32
Recommendations for future policy, research and clinical practice
With an aging population and increasing healthcare costs, a shift from chronic care to more tar-
geted care is inevitable. Enhancing the use of continuous, proactive detection and intervention 
programs is therefore highly recommended. In general, the strategy used in this intervention 
program is expected to keep symptomatic patients longer in primary care, illustrated by the 
decrease in hospitalizations. Most of the current COPD intervention programs only perform one 
time interventions at fixed moments, whereas the MeMO-COPD program facilitates continu-
ous monitoring and targeted interventions. As of the targeted approach, healthcare providers’ 
time for interventions was efficiently spent, making large scale implementation in daily work 
schedules feasible. Especially, when reimbursement of these type of cost-saving interventions 
would be established.
To further optimize intervention strategies, advances in inhalation monitoring technology are 
needed to further foster optimal adherence management. 33 To assess the effect of inhalation 
technique on outcomes, objective, standardized measurements are recommended for future 
studies. In addition, effects of interventions on extent of work productivity could be more 
closely monitored, thereby not only focusing on absenteeism, but also on presentism as both 
have been shown to major impact COPD indirect costs.34 To capture the full scope of exac-
erbations, specifically the mild ones, it is recommend to measure the increase in use of res-
cue medication. As of the high prevalence of comorbidity and polypharmacy, it would also 
be worthwhile to assess the effects of changes in non-respiratory medication adherence on 
COPD patients’ health outcomes. This study showed promising results regarding prevention of 
exacerbations, but lacked a large enough sample size to show significant differences on other 
endpoints. Therefore, confirmative studies using a pragmatic randomized controlled trial design 
are recommended. 
Conclusion
By specifically targeting COPD patients with potential gain for improvement, the MeMO-COPD 
program seems an efficient and cost-saving method to improve patients’ health outcomes. 
Continuous detection of suboptimal pharmacotherapy and risk factors by the pharmacist, fol-
lowed by multidisciplinary interventions by pharmacist, GP, physiotherapist and dietician offers 
potential for targeted and tailored healthcare as opposed to current widespread ‘one-size-fits-
all’ interventions.
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